Article & News

We use non-GLP toxicology to answer early safety questions before a definitive regulatory program is initiated. We align non-GLP procedures and controls with the severity

The study team begins in vitro assay troubleshooting by separating biological variability from technical noise. Before an in vitro pharmacology assay program starts, routine operational choices can

The study team builds reliability in an in vitro pharmacology CRO program through cell identity, assay control, and a traceable evidence path. A reliable in vitro

We use invitro disease biology services to turn a defined mechanism into a controlled and measurable cellular question. The disease-biology assay summary earns confidence only

We help translate cell-based signals into whole-organism evidence through in vivo pharmacology. We strengthen in vivo development controls when an incorrect conclusion would carry greater

We apply in vivo study standards to model selection, animal care, data integrity, study conduct, and interpretation. Our scientific scope includes trained personnel, controlled housing, biosafety procedures,

Outsourcing in vivo pharmacology can broaden model access and connect efficacy with exposure without forcing an internal buildout. The study team uses that flexibility to select

The study team treats CRO compliance as a connected system of controls that keeps every result traceable and reviewable. We verify the materials, methods, and controls

Successful oncology CRO partnerships begin with agreement on what the model must prove, who is responsible for each decision,, and how uncertainty will be handled.

Five warning signs are especially useful when evaluating a CRO relationship: slow scientific communication, inflexible model choice, fragmented services, weak traceability, and conclusions that do